ATLASCardiff Oncology (CRDF) earnings date: Nov 5, 2026
Cardiff Oncology (CRDF) reports earnings for the quarter ended Sep 30, 2026 on Thu, Nov 5, 2026. Analysts expect EPS of -$0.14.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on CRDF
| Last price | $0.84 (-5.5%) |
|---|---|
| Normal 1-day range (±1σ) | ±4.5% |
| Earnings beat history | Beat the EPS estimate in 4 of the last 5 reports |
These figures come from the same calibrated model and valuation as the Cardiff Oncology stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Cardiff Oncology reports on Nov 5, 2026. One email the day before, with ATLAS’s read on Cardiff Oncology. You can switch it off at any time.
Alert me before CRDF reportsFree to start. Creating an account takes under a minute.
Notify me when Cardiff Oncology reports
Track CRDF free Add Cardiff Oncology to a free ATLAS watchlist and see its next report date in one place.
CRDF earnings at a glance
| Next report (confirmed) | Thu, Nov 5, 2026 |
|---|---|
| Time | Not stated |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.14 |
| Last report | Aug 11, 2026 · Beat |
| Beat rate (last 5 reports) | 4 of 5 (80%) |
| Average EPS surprise | +5.5% |
| Average move around a report | ±5.7% (last 5) |
| Sector | Healthcare · Biotechnology |
Cardiff Oncology earnings history: last 5 reports
Cardiff Oncology last reported on Aug 11, 2026: EPS of -$0.14 against an estimate of -$0.16 (+12.5% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 11, 2026 | -$0.16 | -$0.14 | +12.5% | Beat | -3.9% |
| May 14, 2026 | -$0.12 | -$0.18 | -50.0% | Miss | -1.2% |
| Feb 24, 2026 | -$0.20 | -$0.11 | +45.0% | Beat | +22.4% |
| Feb 12, 2026 | $1.03 | $1.07 | +3.9% | Beat | 0.0% |
| Jan 23, 2026 | $1.61 | $1.87 | +16.2% | Beat | -1.0% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for CRDF
See the fair value, the probability range and the earnings history of Cardiff Oncology on its ATLAS page.
Cardiff Oncology (CRDF) stock analysisPlans from €3.99 a month.
Cardiff Oncology earnings: frequently asked questions
When does Cardiff Oncology (CRDF) report earnings?
Cardiff Oncology is scheduled to report on Thursday, November 5, 2026 (the time of day has not been stated). ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for CRDF?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.14 per share (USD). Estimates can change before the report.
How often does CRDF beat earnings estimates?
Of its last 5 reports with a recorded result, Cardiff Oncology beat the EPS estimate 4 times; the average surprise was +5.5%. Past results do not predict the next one.
How much does CRDF move around earnings?
Over its last 5 reports the stock moved an average of 5.7% (absolute, from the close before the report day to the close after it), and finished higher 1 of 5 times.
Did Cardiff Oncology beat earnings estimates last quarter?
Cardiff Oncology last reported on Aug 11, 2026: EPS of -$0.14 against an estimate of -$0.16 (+12.5% surprise), a beat.
How much does CRDF usually move in a day?
On a normal trading day the ATLAS model puts CRDF’s one-day range at about ±4.5%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Thu, Nov 5, 2026
Educational information, not investment advice. Disclaimer